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rug-Induced Atrial Fibrillation
ornelis S. van der Hooft, MD,*‡ Jan Heeringa, MD,* Gerard van Herpen, MD, PHD,†
an A. Kors, PHD,† J. Herre Kingma, MD, PHD,‡§ Bruno H. Ch. Stricker, MB, PHD*‡
otterdam, The Hague, and Groningen, the Netherlands
Atrial fibrillation (AF) is the most common sustained rhythm disorder observed in clinical
practice and predominantly associated with cardiovascular disorders such as coronary heart
disease and hypertension. However, several classes of drugs may induce AF in patients
without apparent heart disease or may precipitate the onset of AF in patients with preexisting
heart disease. We reviewed the literature on drug-induced AF, using the PubMed/Medline
and Micromedex databases and lateral references. Successively, we discuss the potential role
in the onset of AF of cardiovascular drugs, respiratory system drugs, cytostatics, central
nervous system drugs, genitourinary system drugs, and some miscellaneous agents. Drug-
induced AF may play a role in only a minority of the patients presenting with AF.
Nevertheless, it is important to recognize drugs or other agents as a potential cause, especially
in the elderly, because increasing age is associated with multiple drug use and a high incidence
of AF. This may contribute to timely diagnosis and management of drug-induced
AF. (J Am Coll Cardiol 2004;44:2117–24) © 2004 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.053Foundation
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Strial fibrillation (AF) is the most common sustained
hythm disorder observed in clinical practice. Its clinical
mportance is highlighted by a high prevalence and serious
linical consequences such as hemodynamic impairment and
schemic stroke. The prevalence increases with age, up to
% in people over the age of 60 years and approximately 9%
n people over the age of 80 years (1). Atrial fibrillation is
ssociated with a four- to five-fold higher risk of ischemic
troke than the risk in the unaffected population (1–3).
ulticenter studies have addressed the fact that not only
ermanent AF, but also paroxysmal AF, could predispose
atients to systemic embolism (4–6).
Although AF can occur without detectable disease (“lone
F”), it is often associated with heart disease (7). Increasing
ge, heart failure, smoking, diabetes mellitus, hypertension,
ale sex, left ventricular hypertrophy, myocardial infarction,
alvular heart diseases, pulmonary diseases, and hyperthy-
oidism are risk factors for AF (8). Acute, temporary causes
f AF include alcohol intake, stress, coffee in excess, surgery,
eri-/myocarditis, and pulmonary embolism (7).
Also, drugs have been associated with the induction of
F in case reports and clinical trials. In this review, we will
iscuss these drugs and what is known about their potential
echanisms to induce AF. First, we will discuss shortly
hat is known about the etiology and mechanisms of AF to
etter understand the potential mechanisms of drugs to
nduce AF.
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ccepted August 16, 2004.TIOLOGY AND MECHANISMS OF AF
trial fibrillation is associated with morphologic changes in
he atrial myocardium. This may result from AF itself or
rom other underlying disease processes; however, it may
lso be general manifestations of the physiologic aging
rocess. Changes in the autonomic innervation of the atrial
yocardium and sinus and atrioventricular nodes are part of
he normal aging process. Underlying disease may cause
nlargement and structural changes of the atrial myocar-
ium; vascular changes of sinus and atrioventricular nodes;
cute and chronic inflammatory changes with necrosis,
ellular infiltration, fatty metamorphosis, fibrosis, and cal-
ification. These changes in the atrial myocardium lead to
he electrophysiologic abnormalities that result in the mech-
nisms responsible for the occurrence of AF (9). Electro-
hysiologic effects in the atrium leading to AF can also be
aused or triggered by physiologic processes such as adren-
rgic or vagal stimulation, metabolic or electrolyte distur-
ances, or by certain drugs or agents (10). Table 1 gives an
verview of the most important conditions related to AF.
s AF is often associated with other supraventricular
achycardias (SVT), these conditions may also induce other
VT.
Review of the etiologic factors discussed above suggests
hat a common pathway exists among the many diverse
auses of AF. It is postulated that the onset of AF requires
trigger, such as an acute myocardial infarction or an
ntense neurological input to the atrium, or a drug, but that
substrate is also required for the onset and maintenance of
he arrhythmia (11). After cardiac surgery, for instance,
ncreasing age is the most powerful predictive factor for AF.
uperimposed upon the age-related atrial changes are the
riggers of adrenergic stimulation and perioperative pericar-
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Drug-Induced Atrial Fibrillation December 7, 2004:2117–24itis and/or atrial ischemia. The importance of adrenergic
riggers is emphasized by the effect that beta blockade has in
ecreasing the occurrence of AF after a coronary artery
ypass graft (CABG). That this trigger-substrate relation is
critical partnership in arrhythmia production is apparent
rom the fact that AF usually resolves spontaneously within
few weeks after CABG (11). Similarly, if a drug is stopped
hat triggers AF, the arrhythmia will often resolve.
Another postulated proarrhythmic mechanism (12) that
ts the trigger-substrate relation is based on experiences in
ntiarrhythmic therapy and explained in Figure 1. In reality,
or arrhythmias due to re-entry, the mechanisms by which
rugs cause arrhythmia are more complex than the model
iscussed in the legend of Figure 1. We describe this model
nly for basic understanding.
ETHODS
e reviewed published reports on drug-induced AF in
nglish from January 1974 to February 2003 using the
ubMed/Medline and Micromedex (Drugdex) (13) data-
ases and lateral references. We used the key words “atrial
brillation” combined with “drug-induced,” “chemically in-
uced,” “associated with drug,” “as cause of drug,” and “as
ide effect.” Case reports with a very weak and uncertain
ssociation were excluded.
EVIEW OF DRUG-INDUCED AF
t is of clinical importance to recognize drugs or other
gents as a potential cause or trigger of AF, especially in the
lderly, because increasing age is associated with multiple
Abbreviations and Acronyms
AF  atrial fibrillation
CABG  coronary artery bypass graft
SLE  systemic lupus erythematosus
SR  sinus rhythm
SVT  supraventricular tachycardia
able 1. Conditions Related to AF
ardiovascular conditions
Hypertension
Valvular disease
Cardiomyopathy
Coronary heart disease: acute myocardial ischemia and infarction
Peri-/myocarditis
Sick sinus syndrome
Cardiac surgery
Congenital heart disease
oncardiovascular conditions
Pulmonary disease/embolism
Electrolyte abnormalities: e.g., hypokalemia, hyperkalemia
Adrenergic stimulation: hyperthyroidism, pheochromocytoma, fever,
stress, alcohol, caffeine, drugs, neurogenic
Vagal stimulation: neurogenic, drugs
Idiopathic (“lone AF”)pF  atrial fibrillation.rug use and a high incidence of AF. Much has been
ublished about severe proarrhythmic adverse effects of
antiarrhythmic) drugs, especially life-threatening drug-
nduced ventricular tachycardias and conduction disorders.
t is not our aim to review these drug-induced arrhythmias,
ut to focus on drug-induced AF. Atrial fibrillation is
sually not an immediately life-threatening arrhythmia, but
t produces substantial discomfort and morbidity, is a major
eterminant of stroke (4–6), and may increase mortality,
articularly in patients with structural heart disease (10).
rugs may induce different types of SVT and possibly with
similar mechanism. In this review, however, we will focus
n AF because this supraventricular arrhythmia is the most
ommon in clinical practice and known for its serious
omplications and potential permanent character.
Table 2 gives an overview of drugs that may induce AF
nd their potential mechanisms, according to published
eports. In this table can be seen that almost all drug-
nduced AF is reported to have the following main mech-
nisms: adrenergic or vagal stimulation, direct cardio-
oxicity, changing atrial conduction, refractoriness or
utomaticity, coronary vasoconstriction/ischemia, and (lo-
al) electrolyte disturbances. A distinction has been made
etween agents reported in case reports to be associated with
F and agents mentioned in Micromedex to be able to
nduce AF. As far as we could retrieve, no studies have been
igure 1. Antiarrhythmic drugs have diverse electrophysiologic effects on
onduction, refractoriness, and automaticity in the heart. As an example we
ight consider the simplest form of atrial fibrillation (AF) due to re-entry
round one or more obstacles (i.e., scars) that might be found in a patient
ith AF due to prior myocardial infarction. As a re-entry wave front
irculates around an obstacle, it leaves in its wake a region of tissue that is
efractory. In order for re-entry to be sustained around such an obstacle, the
evolution time (RT) around the circuit must exceed the refractory period
RP) (i.e., RT RP). Otherwise, the wave front would begin to encounter
issue that was still refractory, thereby preventing or extinguishing the
e-entry. If RT RP, re-entry is not possible, but when a (antiarrhythmic)
rug slows conduction velocity more than it prolongs the RP, this drug
ould initiate re-entry (RT  RP), and the drug would be judged as
roarrhythmic (arrow b). If a drug prolongs the RP to a greater degree than
t slows conduction velocity, it will prevent re-entry and acts as antiar-
hythmic (arrow a).ublished on drug-induced AF besides case reports.
CC
f
t
r
e
b
o
v
t
l
a
A
c
a
d
a
d
n
s
b
1
o
r
a
a
t
d
r
b
v
u
d
t
c
i
T
C
R
C
C
G
M
*
r
2119JACC Vol. 44, No. 11, 2004 van der Hooft et al.
December 7, 2004:2117–24 Drug-Induced Atrial FibrillationARDIOVASCULAR DRUGS
ardiac stimulants. Several cardiac stimulants are known
or their potential to induce SVT. This can be attributed to
heir adrenergic properties. Atrial fibrillation has been
eported with the use of dobutamine and arbutamine stress
chocardiography (14,15). Dopamine and dopexamine have
een associated with AF when used for acute cardiac failure
r hypotension after open-heart surgery. Some cases con-
erted spontaneously to sinus rhythm (SR), others needed
reatment (16,17). In one case report, an older patient with
eft atrial enlargement developed sustained AF after dobut-
mine stress echocardiography (14).
ntiarrhythmics. It is well known that antiarrhythmics
an have proarrhythmic adverse effects, including AF and
trial flutter (12,18,19). A possible mechanism is previously
escribed and is shown in Figure 1. It is not surprising that
ntiarrhythmic drugs can cause arrhythmia in view of the
iverse electrophysiologic effects on conduction, refractori-
able 2. Drugs* Reported to Potentially Induce AF
Drug Group
ardiovascular
Cardiac stimulants Dopamine, dobutamin
Vasodilators† Flosequinan, isosorbide
Antiarrhythmics Adenosine, verapamil,
Cardiac ultrasound contrast agents† Perflexane, perfluorobu
Cholinergics Acetylcholine
Diuretics Thiazides
espiratory system
Sympathicomimetic inhalants
Alpha agonists Pseudoephedrine
Beta agonists Albuterol‡
Xanthines Aminophylline‡
Corticosteroids Methylprednisolone (h
ytostatics Gemcitabine‡, melpha
5-FU, etoposide, ifo
Cytokines and immunomodulators† Interferon-gamma, int
Photosensitizing agents† Porfimer, verteporfin
entral nervous system
Cholinergics Physostigmine, donepe
Anticholinergics Atropine
Dopamine agonists Apomorphine
Antidepressants Fluoxetine‡
Tranylcypromine, trazo
Antipsychotics Clozapine‡
Antimigraine Sumatriptan‡
Anesthetics Bupivacaine
enitourinary system
Drugs for erectile dysfunction Sildenafil‡
Drugs for premature labor Hexoprenalin, terbutal
Magnesium sulphate
iscellaneous Nicotine, anabolic ster
azathioprine
Antithrombotic agents† Anagrelide, clopidogre
Antiemetica† Alizapride, benzquinam
Miscellaneous† Amifostine, disulfiram,
gallium nitrate, levo
zalcitabine, amphote
Grouped by Anatomical Therapeutic Chemical code; †micromedex (product inf
e-challenge.
AF  atrial fibrillation; 5-FU  5-fluorouracil.ess, and automaticity these agents have in the heart. In dingle cases it has been described that persons treated for AF
y class IA and IC drugs developed atrial flutter with 2:1 or
:1 atrioventricular conduction (19,20). We will focus now
n the specific drugs associated with AF in published
eports.
Adenosine can induce AF by the shortening of atrial
ction potential duration while it is used for terminating
trioventricular re-entry tachycardia. Most patients convert
o SR within a few minutes (21–23), but also a case has been
ocumented that needed electrical cardioversion (24). Case
eports and experiments suggest that the calcium-channel
lockers verapamil (25–27) and diltiazem (28) may aggra-
ate or induce AF in susceptible patients. The mechanism is
nknown. If AF develops in patients given verapamil or
iltiazem for other indications, physicians should consider
he drug as a possible cause of the arrhythmia. Digoxin can
ause all sorts of arrhythmias and conduction disturbances,
ncluding AF (29). Mostly this is a sign of intoxication. If
Mechanism
examine, arbutamine Adrenergic stimulation
onitrate, losartan Hypotension 3 adrenergic reflex?
zem, digoxin, atenolol Changing atrial electrical properties
Local stimulation?
Vagal stimulation
Hypokalemia
Adrenergic stimulation
Adrenergic stimulation
Adrenergic stimulation
ose) Local potassium efflux
isplatin‡, docetaxel,
de†
Several, cardiotoxicity
in-3, interleukin-6 Not reported
Not reported
Vagal stimulation
Adrenergic stimulation
Vagal activity
Serotonin?
Not reported
Not reported
Coronary spasm 3 ischemia
Increasing cardiac automaticity
Hypotension 3 adrenergic reflex?
Adrenergic stimulation
Changing atrial conduction
fluorescein, etanercept, Several
Not reported
Not reported
inate, flupirtine,
ine, nesiritide, niacin,
B, pentagastrin, calcium
Not reported
on/clinical trials) (13); ‡causal relationship confirmed by recurrence of AF afterDrug
e, dop
mon
diltia
tane
igh d
lan, c
sfami
erleuk
zil
done
ine
oids,
l
ide
etret
carnit
ricin
ormatiigoxin is prescribed for heart failure and, after a while, AF
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Drug-Induced Atrial Fibrillation December 7, 2004:2117–24nd/or other arrhythmias develop, this may result from
bsolute or relative digoxin overdose. When digoxin is
rescribed to convert AF to SR and AF reoccurs, it may be
ifficult to assess its causation. In a study of the electro-
hysiologic effects of atenolol, researchers made the obser-
ation that acute use of atenolol could facilitate the induc-
ion of AF in patients with a high incidence of paroxysmal
F and conduction abnormalities. The underlying mecha-
ism is unclear (30).
iuretics. Thiazide diuretics are especially known for hy-
okalemia as a potential side effect. Via this mechanism,
rrhythmia can be induced, and also AF has been reported
31,32). Therefore, regular electrolyte monitoring of pa-
ients using diuretics is essential, and adding potassium-
onserving diuretics can be helpful in patients susceptible to
ypokalemia.
holinergics. Cholinergic drugs stimulate the vagal ner-
ous system. Paroxysmal AF is a relatively common
omplication of coronary artery spasm provocation tests
sing intracoronary injection of acetylcholine, especially
n patients with ischemic heart disease (33). In a study of
40 patients, of the patients who developed AF during
pasm provocation testing (n  116), 28.4% needed
ntiarrhythmic agents for conversion to SR again. The
otential mechanism is thought to be vagal stimulation
y acetylcholine (33).
Some other cardiovascular drugs have been associated
ith AF in clinical trials, such as the vasodilators flose-
uinan and isosorbide mononitrate and the echocardiogra-
hy contrast agents perflexane and perfluorobutane. Poten-
ial mechanisms were not reported (13,34).
ESPIRATORY SYSTEM DRUGS
ympathicomimetic inhalants. Alpha and beta sympathi-
omimetic inhalants are prescribed to induce bronchodila-
ion in lung patients. They are known for their potential to
ause cardiovascular adverse effects, such as sinus tachycar-
ia and exacerbation of existing arrhythmia. Atrial fibrilla-
ion has been reported in infants 1 year of age after
xcessive therapeutic doses of pseudoephedrine (4 mg/kg/
ay) (35). Albuterol treatment using a spacer device was
eported to induce AF with a positive re-challenge in a
ealthy young man. The authors think that the high dose
dministered through the spacer triggered the AF, because
he man did not have complaints using a metered dose
nhaler without the spacer device (36).
anthines. The positive-inotropic, arrhythmogenic, and
hronotropic effects of xanthines are well known (37–39).
trial fibrillation associated with intravenous aminophylline
as been reported in three patients without underlying
ardiac disease. Re-challenge was positive in one patient
39). Conversion to SR occurred 9 to 14 h after cessation of
he drug in all three patients.
orticosteroids. High doses of corticosteroids are standardreatment for a wide array of medical disorders. There are reveral case reports of AF after pulse methylprednisolone
herapy: in two patients with multiple sclerosis (40,41), two
hildren with nephrotic syndrome (one of them having
ystemic lupus erythematosus [SLE]) (42), in a man with
LE (43), and in a woman with rheumatoid arthritis (44).
ujimoto et al. (45) postulated that methylprednisolone
ediates potassium efflux via a direct effect on the cell
embrane. Local potassium efflux may, in turn, influence
rrhythmogenesis.
YTOSTATICS
he pathophysiology of chemically induced arrhythmias by
ytotoxic agents remains to be clarified. The hypotheses are
ultiple and include direct and indirect effects. The sinus
ode may be influenced by several stimuli, and a hyper-
timulation of the parasympathic as well as of the sympathic
ystem may cause abnormal function of the sinus node and
bnormal intraatrial or atrioventricular conduction (46,47).
nthracyclines are associated with cardiac toxicity and
rady- or tachyarrhythmias. Cisplatin, 5-fluorouracil, and
toposide have most frequently been associated with AF
47). In cases of cisplatin-induced AF, a positive re-
hallenge confirmed a causal relationship. The authors
ttributed this to direct myocardial toxicity (48). Gemcit-
bine has been reported to induce AF with a positive
e-challenge in a patient who had a history of a single brief
aroxysm of AF (47). The authors suggested a direct toxic
ffect of gemcitabine on the sinus node and/or the supraven-
ricular conduction system. Ciotti et al. (49) describe an-
ther possible mechanism. They reported a case of severe
ardiopulmonary toxicity (acute respiratory distress syn-
rome and AF) after gemcitabine infusion and suggest an
nflammatory pathogenetic mechanism mediated by cyto-
ine release resulting in myofibroblast proliferation and
ollagen deposits in lung and atrium.
Atrial fibrillation after high-dose melphalan has been
escribed in several cases without a history of structural
eart disease or any other condition potentially causing AF
uch as fever, septicemia, or electrolyte imbalance (50). A
ossible mechanism is not discussed. The authors speak of
cute conduction cardiotoxicity.
Docetaxel-induced AF was recently described in a
oman without any risk factors for AF (51). The authors
onclude that this is probably a rare adverse effect of
ocetaxel.
In all cases mentioned previously, SR was reestablished by
ntiarrhythmic drug therapy.
ENTRAL NERVOUS SYSTEM DRUGS
Anti)cholinergics. Cardiac dysrhythmias are among the
ajor adverse reactions of the anticholinergic and vagal
nhibitory agent atropine. Ophthalmic atropine eye drops
fter glaucoma surgery have been associated with AF. Two
ases have been described, and AF resolved after antiar-
hythmic treatment (52).
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December 7, 2004:2117–24 Drug-Induced Atrial FibrillationThe cholinergic agent physostigmine, a cholinesterase
nhibitor and vagal stimulator, is commonly used to treat the
entral anticholinergic syndrome or post-anesthetic depres-
ion caused by a large number of drugs. One case report
escribes the occurrence of AF directly after the adminis-
ration of physostigmine (53). The mechanism is thought to
e due to severe depression of both the sinoatrial and
trioventricular nodes due to vagal tone. This allows a latent
e-entry focus to emerge within the atrial myocardium.
Also, donepezil, a cholinesterase inhibitor used in
lzheimer’s disease, has been associated with AF in
linical trials (13).
opamine agonists. Apomorphine, a dopamine receptor
gonist used in Parkinson’s disease, has been associated with
F in a man without cardiovascular disease (54). Five
inutes after a subcutaneous bolus of apomorphine, the
an developed AF and was converted to SR after medical
reatment. Other possible causes for AF were excluded.
ubcutaneous apomorphine injection has been reported to
ause postural hypotension and vasovagal response in 10%
f patients with Parkinsonism (55). The authors state that
F in this patient may have been induced by an imbalance
f autonomic tone with increased vagal activity.
ntidepressants/antipsychotics. The selective serotonin
euptake inhibitor fluoxetine has been reported to provoke
F and a recurrence on re-challenge in an elderly woman
ith a history of mild stable angina, but no history of
rrhythmia or myocardial infarction (56). Because serotonin
as an important role in the homeostatic control of the
ardiovascular system, selective serotonin reuptake inhibi-
ors can be expected to cause hemodynamic changes (57).
he authors state that, in this woman with (mild) preexist-
ng heart disease, the cardiovascular effects of fluoxetine may
ave been able to trigger the onset of AF.
Similarly, the occurrence of AF after the use of the
onoamine oxidase inhibitor tranylcypromine has been
escribed in a young man without cardiovascular past but a
istory of alcohol abuse. A possible mechanism mentioned
n this report is stimulation of cardiac catecholamine recep-
ors by a decreased catabolism of tranylcypromine in an
lcohol-damaged liver (58). The atypical antidepressant
razodone has been associated with AF in a patient with
nderlying heart disease (59).
The atypical antipsychotic clozapine has been reported to
nduce AF with a positive re-challenge in a man without
ardiovascular history. Antiarrhythmic therapy was needed
o convert to SR again. A potential mechanism is not
escribed. Other side effects of clozapine such as orthostatic
ypotension, sinus tachycardia, heart failure, and electrocar-
iogram changes are well known (60).
ntimigraine drugs. The antimigraine drug sumatriptan, a
erotonin-1 agonist, has frequently been associated with
hest pain and myocardial infarction (61–64). This is
resumed to be due to vasoconstriction of the coronary
rteries. Atrial fibrillation associated with sumatriptan is
ncommon, but several cases have been reported, also with dositive re-challenge (65). The authors suggest that myo-
ardial ischemia secondary to coronary vasospasms could be
trigger for AF. This mechanism is also postulated by
ung et al. (66). Hung et al. (66) described a patient who
egularly developed paroxysmal AF after early morning
hest tightness. Medical history only mentioned well-
ontrolled hypertension. Coronary artery spasm provocation
ith methylergonovine was performed to test whether AF
as the result of coronary artery spasm. The patient indeed
eveloped AF during the provocation test. Sueda et al. (33)
eported that paroxysmal AF often occurred during spasm
rovocation tests with acetylcholine, especially in patients
ith ischemic heart disease. They suggested that vagal
timulation by acetylcholine triggered the onset of AF in
usceptible patients. However, the mechanism may also be
yocardial ischemia secondary to coronary vasospasms, as
escribed previously.
nesthetics. Atrial fibrillation has been described during
pidural anesthesia with bupivacaine in a man with a history
f stable angina pectoris but no arrhythmias (67). The AF
ersisted despite treatment during the period of epidural
lockade. Only after the anesthesia was terminated, rever-
ion to SR occurred. The reporters suggest that bupivacaine
nhibits the Na K pump, hence reducing the resting cell
embrane potential. This may increase cardiac automatic-
ty, especially in cardiac fibers already partially depolarized
ecause of ischemic heart disease. The authors postulate
hat bupivacaine acted as a trigger for the onset of AF.
ENITOURINARY SYSTEM
rugs for erectile dysfunction. Three case reports de-
cribe AF after taking sildenafil (68–70). One occurred in a
ealthy young man who interrupted coitus because he felt
ight-headed and had palpitations that were followed by a
rief syncopal episode (68). He failed chemical conversion
wice, but converted spontaneously to SR two days later. It
as suggested that sildenafil caused profound hypotension
eading to syncope and reflex tachycardia via catecholamine
xcess. Another report describes a 50-year-old man with a
ypertrophic cardiomyopathy who developed AF with diz-
iness and converted to SR after medical treatment (70).
his man had a positive re-challenge several weeks later. A
hird report describes AF and hypotension in a man 1 h
fter taking sildenafil (69). He was diagnosed with a
olff-Parkinson-White syndrome 12 years before. Four
ours later, he returned to SR spontaneously. The authors
peculate that AF was caused by increased sympathetic
ctivity due to hypotension, which may be provoked by
ildenafil.
RUGS FOR PREMATURE LABOR
exoprenaline is a beta-adrenergic agonist used for treat-
ent of premature labor. Atrial fibrillation has been re-
orted in a young woman without cardiovascular disease
uring intravenous treatment with hexoprenaline (71); 8 h
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Drug-Induced Atrial Fibrillation December 7, 2004:2117–24fter cessation of the drug, the heart rate spontaneously
onverted to SR. The authors state that it is reasonable to
xpect that arrhythmias and other adrenergic adverse effects
ay occasionally be produced by this drug.
Oral use of terbutaline, also a beta-sympathomimetic
rug, has been associated with AF in a healthy pregnant
oman with preterm labor. After several attempts of med-
cal antiarrhythmic treatment, she converted to SR (72).
Magnesium sulfate has widespread use in pregnancy both
n preeclampsia as an anticonvulsant drug and as a tocolytic
rug. In a woman with preeclampsia and without history of
ardiac disease, AF occurred during treatment with magne-
ium sulphate and resolved spontaneously after discontinu-
tion. This drug has antiarrhythmic properties by slowing
he conduction in the atrioventricular node, but in this case
robably induced AF. Serum levels were within therapeutic
ange (73).
ISCELLANEOUS
part from the categories of drugs discussed in the previous
aragraphs, various other agents have been associated with
he occurrence of AF.
Nicotine is widely used as an aid to smoking withdrawal.
here are several reports of nicotine induced AF (74–76).
icotine overdose taken as chewing gum or nasal inhalator
an result in increased heart rate and can be a potential
anger for developing AF, even in individuals without a
istory of cardiac disease. Atrial fibrillation has also been
escribed in a patient with mild cardiovascular disease
aking the usual amount of nicotine gum (75).
High doses of anabolic steroids have been reported in
ssociation with AF (77), as with hypertension, ischemic
eart disease, hypertrophic cardiomyopathy, and sudden
eath. A healthy 22-year-old male bodybuilder developed
ymptomatic AF after taking high doses of anabolic steroids
or five weeks. An echocardiogram showed some left atrial
ypertrophy and septal hypokinesis, but it remained unclear
f this was caused by the steroids. He was hospitalized and
onverted spontaneously to SR after two days of stopping
he intake of the steroids. Atrial fibrillation did not recur
fter discharge.
Intravenous fluorescein has been associated with AF. A
6-year-old man with negative cardiac history developed
F just after administration of fluorescein during ankle
urgery. Cardioversion was eventually required to restore
R. Adverse reactions to fluorescein are not rare and
requently take the form of an allergic reaction. The authors
uggest that nonspecific histamine-releasing mechanisms
an explain the onset of AF in this patient, because
istamine has long been known to have effects on cardiac
hythm through several different mechanisms (78,79).
A patient without risk factors for AF has been reported
eveloping AF after a combination of etanercept and
ethotrexate for rheumatoid arthritis (80). The authorspeculate that blocking tumor necrosis factor-alpha recep- aors with etanercept could cause increased intracellular
alcium in the myocyte and perhaps make the myocyte more
xcitable.
Azathioprine, an immunosuppressive agent used in severe
soriasis, has been associated with AF, but one of the
eported patients abused alcohol and developed high fever
hile using azathioprine. Such factors could also have been
esponsible for triggering AF (81,82). The other reported,
lso speculative, case had no comorbidity and developed AF
fter four weeks of use. Other known possible causes for AF
ere excluded, and AF persisted for at least one year.
ISCUSSION
here are different pathways to the initiation of AF.
herefore, it is not surprising that several categories of drugs
ith different mechanisms of action have been associated
ith the onset of AF. Evidence associating drugs with AF
s scanty and largely based on individual case histories. Even
n cases in which a close temporal relationship between drug
ntake and initiation of AF exists, this may be a chance
nding or be caused by the underlying condition (“con-
ounding by indication”). Nevertheless, in several cases
ecurrence of AF after re-challenge confirmed a causal
elationship. Such proof is not very common, however, as
e-challenge is only ethical when it concerns a drug that is
ssential for the treatment of the patient and when a causal
ole of the drug is still inconclusive. However, if other
nown possible causes for AF are excluded and a plausible
echanism is available, the likelihood of a causal relation-
hip increases. Pathophysiologically, drugs that increase or
ecrease adrenergic or vagal activity, such as sympathicomi-
etics, parasympathicomimetics, and their inhibitors, may
e able to cause AF, especially in susceptible patients with a
istory of cardiovascular disease (disease is the substrate,
rug is the trigger), but also in “healthy” patients. These
rugs represent a substantial part of cardiovascular, respira-
ory, and central nervous system medications. Antiarrhyth-
ic drugs can paradoxically induce dysrhythmias as well,
ncluding AF and atrial flutter, by influencing the electrical
roperties of the atrial myocardium. Coronary spasm in-
uced by certain drugs, such as acetylcholine and
umatriptan, may cause AF via myocardial ischemia. Cyto-
tatics seem to have a more direct toxic effect on the heart,
otentially initiating AF. The underlying disease and drug
ogether can play an important role in the induction of AF
substrate-trigger relation), especially in thorax or lung
arcinoma.
Most of the time it is not difficult to diagnose drug-
nduced AF because there is a direct time relationship
etween the administration of the drug and the onset of AF.
owever, if a patient presents with new-onset AF, it should
e routine to review, besides the medical history, what
edication or other agents the patient is using that may be
ble to induce AF. If there is suspected drug-induced AF
fter exclusion of other causes, the suspected drug/agent
s
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December 7, 2004:2117–24 Drug-Induced Atrial Fibrillationhould be stopped and AF treated if it persists after
iscontinuation. It may be important to have an idea about
he underlying cause or mechanism, and, if overdose is not
he issue, it may be advisable to find an alternative drug or
reatment for the condition the drug was given for. If the
rug is necessary for the patient, it may be advised to restart
he drug in a lower dose and monitor the patient adequately
or recurrence of AF. If AF recurs, continuous treatment to
ontrol AF is needed.
Much has been published, including observational stud-
es, about severe proarrhythmic side effects of drugs, espe-
ially life-threatening drug-induced ventricular arrhythmias
requently associated with QT interval prolongation. Epi-
emiologic studies to quantify the relation between certain
rugs and AF have not been performed yet, although AF is
very common arrhythmia with substantial morbidity and
otentially serious complications. We think more research is
eeded, such as experimental and observational studies, to
et more insight into the effect of drugs on the development
f AF.
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